|
Up a level |
Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.
Falchook, Gerald S; Long, Georgina V; Kurzrock, Razelle; Kim, Kevin B; Arkenau, Tobias H; Brown, Michael P; Hamid, Omid; Infante, Jeffrey R; Millward, Michael; Pavlick, Anna C; O'Day, Steven J; Blackman, Samuel C; Curtis, C Martin; Lebowitz, Peter; Ma, Bo; Ouellet, Daniele; Kefford, Richard F (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet, 379(9829):1893-1901.